DUNCAN BARBARA GAYLE 4

What Happened

• Barbara Gayle Duncan, a director of Atea Pharmaceuticals (AVIR), reported compensation-related equity activity dated June 18, 2026. The Form 4 shows RSU awards and a derivative exercise/conversion: 26,700 and 37,700 RSUs were recorded as acquired (awards), and a derivative exercise/conversion of 29,600 shares was reported as both acquired and disposed, all at $0. These transactions reflect awards/vestings and a conversion/exercise of a derivative instrument, not an open-market purchase or cash sale.

Key Details

• Transaction date: June 18, 2026; Filing date: June 23, 2026 (filed five days after the transaction).
• Reported items: Exercise/conversion (code M) of 29,600 derivative shares @ $0; two grant/award entries (code A) for 26,700 and 37,700 RSUs @ $0.
• Shares/values: All entries recorded at $0 in the filing; no cash proceeds or market purchases reported.
• Shares owned after the transactions: not specified in the information provided from the filing.
• Notable footnotes:
  • F1: Each RSU equals a contingent right to one common share.
  • F2: One RSU grant vested in full on June 18, 2026.
  • F3: Another RSU grant vests in a single installment on the earlier of the next annual meeting after June 18, 2026 or June 18, 2027, subject to continued service.
  • F4: The option vests in 12 equal monthly installments beginning June 18, 2026, fully vested June 18, 2027, subject to continued service.
• Timeliness: The Form 4 was filed June 23 for a June 18 transaction — this appears later than the typical 2-business-day Form 4 deadline.

Context

• These entries are compensation-related (RSU awards and a derivative exercise/conversion). RSUs represent a contingent right to receive shares when they vest. The filing lists a “disposed” entry for 29,600 derivative shares at $0 but does not explain the disposition reason (e.g., settlement mechanics or other administrative actions); the Form 4 does not indicate an open-market sale. Such vestings/exercises are common for insiders receiving compensation and do not by themselves signal a buy or sell intent in the market. For full details, consult the complete Form 4 filing (Accession 0001193125-26-279721).